Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with
advanced non-small cell lung cancer.